A third vaccine contract with Pfizer and Biotech was finalized by The European Union’s executive arm. The contract that deals through 2023 for an additional 1.8 billion doses of their COVID-19 shot to share between the bloc’s countries except for Hungary. Hungary, which opted out of the deal.
Third Vaccine Contract For The EU
The contract, which was agreed on behalf of all 27 EU countries earlier this month, will allow the purchase of 900 million doses of the current vaccine shot and a serum adapted to the virus’ variants. There is an option to purchase an extra 900 million vaccines.
Hungary decided not to be part of the new purchase agreement that followed previous agreements for 600 million shots. However, EU nations agreed to keep on with their strategy of buying doses collectively.
The signing of the new agreement comes less than a week before a court hearing in Brussels which pits the Commission against the pharmaceutical company AstraZeneca. The pharm co has been accused by the EU of failing to deliver the promised number of doses of its vaccine.
The mass production of these doses will be based in the EU, and the essential components will be sourced from the region. The Commission assures that this will guarantee delivery. With AstraZeneca’s contract with the EU, they are foreseeing an initial 300 million doses for distribution among the Eu member countries. There is an option for a further 100 million. The doses are expected to be delivered throughout 2021, but only 30 million doses have been sent during the first quarter. The Commission established that the company is set to provide only 70 million doses. This is in place of the 180 million dollars it had promised.
The EU noted that there was a sharp contrast in the relationship they have with AstraZeneca and the one they have with Pfizer. However, there is a well-established cooperation and this ensures that they will be timely deliveries.
Through the U.N-backed effort known as COVAX, the Commission noted that they will be donating vaccines to non-EU countries through the program providing vaccines to low- and middle-income countries.
The EU now prioritizes vaccine technologies “that have over time proven their worth, like the mRNA vaccines.”
The active component in the Pfizer-Biotech shot is messenger RNA or mRNA. This ingredient consists of instructions for human cells to build a harmless piece of the coronavirus called the spike protein. Upon infection, the human immune system recognizes the spike protein as foreign allows it creates a response against the virus.
Kyriakides said, “But we are keeping our options open. The past months have taught us clearly that there is a need to have access to a broad portfolio of vaccines and different advanced technologies. Above all, we need reliable partners. As well as reliable partners…”
EU Commission president Ursula von der Leyen, at an event by Germany’s WDR public television, told the EU that, by the end of this week, 260 million doses of vaccine will be delivered to Europe. Some countries such as the U.S. and U.K. that have been put into perspective over time were faster to start with.
The covid vaccine was a success despite its criticized slow start.
In the beginning, there was a lot of criticism. Yes, there was a lot of criticism of the European Union at the beginning broadcast Thursday. However, what is important that the EU delivers vaccines to its 450 million citizens day by day, and the vaccine is a success.